Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2009.04048.x ◽

2009 ◽

Vol 30 (4) ◽

pp. 343-351 ◽

Author(s):

M. NAGAKI ◽

M. SHIMIZU ◽

J. I. SUGIHARA ◽

E. TOMITA ◽

C. SANO ◽

...

Keyword(s):

Clinical Trial ◽

Hepatitis C ◽

Treatment Duration ◽

Extended Treatment

Download Full-text

141 EXTENDED TREATMENT DURATION IN CHRONIC HEPATITIS C GENOTYPE 1-INFECTED SLOW RESPONDERS: FINAL RESULTS OF THE SUCCESS STUDY

Journal of Hepatology ◽

10.1016/s0168-8278(09)60143-4 ◽

2009 ◽

Vol 50 ◽

pp. S58 ◽

Author(s):

M. Buti ◽

Y. Lurie ◽

N.G. Zakharova ◽

N.P. Blokhina ◽

A. Horban ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Treatment Duration ◽

Extended Treatment

Download Full-text

Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin

Alimentary Pharmacology & Therapeutics ◽

10.1111/j.1365-2036.2008.03628.x ◽

2008 ◽

Vol 27 (9) ◽

pp. 810-819 ◽

Author(s):

K. H. TANG ◽

E. HERRMANN ◽

I. PACHIADAKIS ◽

E. PAULON ◽

N. TATMAN ◽

...

Keyword(s):

Clinical Trial ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Treatment Duration ◽

Individualized Treatment ◽

Download Full-text

Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeksvs72 weeks of pegylated interferon and ribavirin

Journal of Viral Hepatitis ◽

10.1111/j.1365-2893.2010.01374.x ◽

2010 ◽

Vol 18 (4) ◽

pp. e99-e103 ◽

Author(s):

M. Parikh ◽

A. Singh ◽

G. Sood

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Treatment Duration ◽

Meta Analysis ◽

Pegylated Interferon ◽

Extended Treatment ◽

Treatment Naïve

Download Full-text

Extended treatment duration overcomes the requirement for profound week-4 interferon responsiveness in order for hepatitis C genotype 1 patients with unfavorable IL-28B genotype to achieve sustained virologic response

Journal of Clinical Virology ◽

10.1016/j.jcv.2013.04.017 ◽

2013 ◽

Vol 57 (4) ◽

pp. 381

Author(s):

Hidenori Toyoda ◽

Takashi Kumada

Keyword(s):

Hepatitis C ◽

Sustained Virologic Response ◽

Treatment Duration ◽

Virologic Response ◽

Extended Treatment

Download Full-text

T1988 Extended Treatment Duration for Treatment Naive Chronic Hepatitis C Genotype 1 Late Viral Responders: A Meta-Analysis Comparing 48 Weeks vs. 72 Weeks of Pegylated Interferon and Ribavirin

Gastroenterology ◽

10.1016/s0016-5085(10)63884-x ◽

2010 ◽

Vol 138 (5) ◽

pp. S-843

Author(s):

Mehul Parikh ◽

Amanpal Singh ◽

Gagan Sood

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Treatment Duration ◽

Meta Analysis ◽

Pegylated Interferon ◽

Extended Treatment ◽

Treatment Naïve

Download Full-text

Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin

Yearbook of Gastroenterology ◽

10.1016/s0739-5930(08)70203-4 ◽

2007 ◽

Vol 2007 ◽

pp. 255-256

Author(s):

G.A. Makar

Keyword(s):

Hepatitis C Virus ◽

Hepatitis C ◽

Treatment Duration ◽

Extended Treatment ◽

Peginterferon Alfa

Download Full-text

Faculty of 1000 evaluation for Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717965604.793466618 ◽

2012 ◽

Author(s):

Alex Thompson

Keyword(s):

Clinical Trial ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Pegylated Interferon ◽

Randomised Clinical Trial ◽

Combination Regimen ◽

Treatment Naïve

Download Full-text

Faculty Opinions recommendation of Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718087883.793484663 ◽

2013 ◽

Author(s):

Cihan Yurdaydin

Keyword(s):

Clinical Trial ◽

Hepatitis C ◽

Randomized Clinical Trial ◽

Treatment Characteristics

Download Full-text

Head-to-head clinical Trial of Sofosbuvir plus Daclatasvir or Simeprevir for 12 weeks in Non-cirrhotic subjects with significant fibrosis infected with chronic Hepatitis C Virus genoType 1 (TNT-1 Study)

International Journal of Infectious Diseases ◽

10.1016/j.ijid.2018.04.4264 ◽

2018 ◽

Vol 73 ◽

pp. 376

Author(s):

H. Pott Junior ◽

G. Bricks ◽

G. Grandi ◽

J. Senise ◽

A. Castelo

Keyword(s):

Clinical Trial ◽

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Virus Genotype ◽

Significant Fibrosis ◽

Chronic Hepatitis C Virus

Download Full-text

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilisation Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy

Value in Health ◽

10.1016/j.jval.2014.08.2537 ◽

2014 ◽

Vol 17 (7) ◽

pp. A680-A681

Author(s):

H. Akpo ◽

K. Cerri ◽

U. Sbarigia ◽

J. Kleintjens

Keyword(s):

Hepatitis C ◽

Adverse Events ◽

Antiviral Therapy ◽

Treatment Duration ◽

Resource Utilisation ◽

Medical Resource ◽

Treatment Naïve ◽

Download Full-text